Qualyst Transporter Solutions, LLC Announces Launch of New Hepatotoxicity Offering

Investigative bilirubin contract research services that focus on explaining hyperbilirubinemia

RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2012 /PRNewswire-iReach/ -- Qualyst Transporter Solutions, LLC, has launched a contract research service using a clinically-relevant model to assess a compound's potential to alter the transport and metabolism of bilirubin.  Changes in the concentration of bilirubin and/or its metabolites in the blood circulation are one of the more common toxicities observed in drug development. 

The concentrations of bilirubin and its metabolites in the blood circulation is a function of the uptake of bilirubin into the liver, metabolism by the liver, and excretion of bilirubin and metabolites into the bile or back into the blood.  Interactions at any of these steps can cause increases in the circulating concentrations of bilirubin and/or its metabolites, leading to toxicities in the liver or other areas of the body.  "An integrated in vitro system, like sandwich-cultured hepatocytes, with multiple expressed, localized, and functioning, uptake and efflux transporters, and metabolic capacity is required to accurately predict and describe in vivo alterations in bilirubin disposition," said Dr. Kenneth R. Brouwer, CSO for Qualyst Transporter Solutions.  "Utilizing the gold-standard hepatocyte model, we have applied our clinically-relevant B-CLEAR® technology to evaluate the potential of compounds to alter the transport and metabolism of bilirubin," said Dr. Christopher Black, CEO for Qualyst Transporter Solutions.

Bilirubin contract research services can be performed in hepatocytes from all major toxicology species, including humans.  Using Transporter Certified™ hepatocytes, which are fully transporter competent sandwich-cultured hepatocytes, an assessment is performed on a compound's effects on the uptake of bilirubin into the liver, its metabolism of bilirubin to its two primary metabolites (glucuronide conjugates) and the excretion of bilirubin and/or its metabolites into the bile or back into the blood.  Quantitation is performed using LC/MS analytical methods for both bilirubin and its two metabolites.  "Properly designed experiments allow you to determine the mechanistic basis for changes in blood concentrations of bilirubin and its metabolites as well as correlate with potential hepatotoxicity," said Dr. Brouwer.

Taken together with the cholestasis offering, which determines the effect of a compound on the disposition of bile acids, these services offer the opportunity to predict the two most common hepatotoxicities observed in drug development.  Qualyst Transporter Solutions uses only Transporter Certified™ hepatocytes to examine the potential for in vivo-relevant transporter/metabolism-based alterations in the disposition of bilirubin.  The key to obtaining in vivo-relevant answers is to use a fully integrated, functioning, certified cell system.  "We certify our hepatocytes to ensure a fully functioning complement of uptake and efflux transporters, which guarantees the results are in vivo-relevant and reproducible," said Dr. Brouwer.

About Qualyst Transporter Solutions, LLC

Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for drug discovery and development.  Qualyst Transporter Solutions products provide answers to transporter questions that arise in drug discovery and development.  For additional information, please refer to the company's web site at www.qualyst.com or call (919) 313-6500.

Media Contact: Chris Black Qualyst Transporter Solutions, 9193136500, chrisblack@qualyst.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Qualyst Transporter Solutions, LLC



Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services

Need Help